Retrophin, Inc.
Records under this name other than patents Retrophin, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 9 of 9 · Back to Retrophin, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,864,197 | Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders Formerly held In force · High confidence | In force | High confidence | |
| US 11,207,299 | Biphenyl Sulfonamide Compounds for the Treatment of Type IV Collagen Diseases Formerly held In force · High confidence | In force | High confidence | |
| US 9,181,286 | Pantothenate derivatives for the treatment of neurologic disorders Lapsed on the fee record Ended Nov 10, 2023 · USPTO record | Lapsed on the fee record | Ended Nov 10, 2023 | USPTO record |
| US 10,407,447 | Pantothenate derivatives for the treatment of neurological disorders Lapsed on the fee record Ended Sep 10, 2023 · USPTO record | Lapsed on the fee record | Ended Sep 10, 2023 | USPTO record |
| US 10,364,263 | Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders Lapsed on the fee record Ended Jul 30, 2023 · USPTO record | Lapsed on the fee record | Ended Jul 30, 2023 | USPTO record |
| US 8,673,883 | Pantothenate derivatives for the treatment of neurologic disorders Lapsed on the fee record Ended Mar 18, 2022 · USPTO record | Lapsed on the fee record | Ended Mar 18, 2022 | USPTO record |
| US 9,896,464 | Pantothenate derivatives for the treatment of neurological disorders Lapsed on the fee record Ended Feb 20, 2022 · USPTO record | Lapsed on the fee record | Ended Feb 20, 2022 | USPTO record |
| US 9,629,862 | Pantothenate derivatives for the treatment of neurologic disorders Lapsed on the fee record Ended Apr 25, 2021 · USPTO record | Lapsed on the fee record | Ended Apr 25, 2021 | USPTO record |
| US 9,023,793 | Intranasal carbetocin formulations and methods for the treatment of autism Lapsed on the fee record Ended May 5, 2019 · USPTO record | Lapsed on the fee record | Ended May 5, 2019 | USPTO record |